Format

Send to

Choose Destination
Sci Transl Med. 2017 Nov 1;9(414). pii: eaao1690. doi: 10.1126/scitranslmed.aao1690.

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Author information

1
Blueprint Medicines, Cambridge, MA 02139, USA.
2
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Belgium 3000.
3
VA Health Care System and Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.
4
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
5
Blueprint Medicines, Cambridge, MA 02139, USA. clengauer@blueprintmedicines.com.

Abstract

Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs. This rationale is presented for BLU-285, a clinical stage inhibitor of oncogenic KIT and PDGFRA alterations, including activation loop mutants that are ineffectively treated by current therapies. BLU-285, designed to preferentially interact with the active conformation of KIT and PDGFRA, potently inhibits activation loop mutants KIT D816V and PDGFRA D842V with subnanomolar potency and also inhibits other well-characterized disease-driving KIT mutants both in vitro and in vivo in preclinical models. Early clinical evaluation of BLU-285 in a phase 1 study has demonstrated marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations.

PMID:
29093181
DOI:
10.1126/scitranslmed.aao1690
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center